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Background: A modest (41%) reduction in abdominal aortic aneurysm (AAA) growth rate is likely to delay AAA-related
events (surgery or rupture) by 5 years, making the notion of AAA medical treatment very appealing. Randomized
controlled trials of commonly used existing medications are expensive and ethically questionable. This study reviewed the
independent associations of commonly used medications and AAA growth during a 25-year period of AAA surveillance.
Methods:The study included all patients monitored through an AAA screening and surveillance program. Records of AAA
size, risk factors, outcomes, death, and medications were entered into a continually updated database. AAA growth rates
were calculated using a flexible hierarchical model. A multivariate model was used to test for associations independent of
confounders.
Results: The study comprised 1269 patients (94.1% men) who had a mean age of 67 years. The median starting diameter
was 35 mm, the end diameter was 44 mm, and follow-up was 3.4 years. Drugs used in the treatment of diabetes were
associated with a 56% reduction in AAA growth rate (P  .01) independent of confounding factors, including other
therapeutic agents (P  .003). Angiotensin-receptor blockers and potassium-sparing diuretics were also associated with
slower AAA growth rates, although these effects were not independent of all confounders.
Conclusion: Diabetes or its medications, or both, have a negative effect on AAA growth. Because of polypharmacy,
demonstrating the independent effects of individual drugs affecting the renin-angiotensin system was not possible. In
light of this analysis, however, strong associations between angiotensin-receptor blockers and aldosterone-receptor
blockers and slowed AAA progression are credible. ( J Vasc Surg 2010;52:55-61.)Abdominal aortic aneurysm (AAA) disease is a com-
mon life-threatening condition in the Western world with
an increasing prevalence. The adoption of large-scale
screening programs for men at risk (age 65 years), de-
signed to identify and monitor small aneurysms, provides a
window for medical therapy, which has yet to be fully
explored. Less than one-third of all men identified with a
small AAA through screening come to repair within a
4-year period,1 and only half of those considered fit for
surgery at diagnosis will have undergone repair at the end of
a 5-year period.2,3 This reflects an average time to interven-
tion for screen detected AAA patients of between 4 and 6
years and provides an opportunity for therapies designed to
slow AAA disease progression.
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doi:10.1016/j.jvs.2010.02.012Extrapolation of linear growth rates published by this
unit demonstrate that a modest 41% reduction in growth
rate could delay intervention for the median screened AAA
of 35 mm by 5 years (mean linear growth rate of 2.81
mm/y).4 At an average of 7.1 years to reach 55 mm from a
35-mm starting diameter, a growth rate of 1.66 mm/y (a
41% reduction) delays to 12.1 years the average time to
reach 55 mm.
The two aims of medical therapies are to reduce comor-
bidity from concomitant cardiovascular disease and to
modify AAA disease progression (ie, reduce the risk of AAA
rupture).5 The universally used measure of rupture risk is
AAA diameter. It is generally assumed that therapies
achieving slowed AAA growth or relative decreases in AAA
diameter will result in a reduced rupture risk. The patho-
physiology of AAA rupture is complicated, however, and it
may be that some therapeutic effects on AAA rupture
cannot be reported through AAA size alone.6 Modelling
AAA growth rate over time can predict AAA diameter and
infer AAA rupture risk. If AAA growth rate can be modified
by medical therapy, it implies that the risk of rupture will
also be altered. If the time to AAA surgical intervention can
be delayed sufficiently that the risks presented by other
comorbidities begin to outweigh those of AAA rupture, an
expensive and potentially dangerous intervention can be
avoided.
Despite the enormous potential for disease-modifying
drugs, evidence is lacking, and there is currently no ac-
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expansion. Expensive randomized controlled trials have
struggled to obtain adequate numbers, whereas retrospec-
tive studies have yet to overcome difficulties of confound-
ing factors. New randomized controlled trials looking at
the effect of widely used medications such as statins and
renin-angiotensin system modulators on AAA growth are
likely to encounter difficulties in obtaining ethical approval.
Currently, level B and C evidence from small studies sug-
gests that roxithromycin, doxycycline, and statins reduce
AAA expansion rates,7 and evidence from a large linked
administrative database suggests that angiotensin-converting
enzyme (ACE) therapy may protect from AAA rupture.8
This study reviewed the independent associations of
commonly used medications and AAA growth from a 25-
year period of AAA surveillance. To overcome problems of
confounding factors, a novel method of comparing AAA
growth rates within a multivariate model was used.
METHODS
Ethics approval for the study was sought and obtained
from the West Sussex local Research Ethics Committee
(Ref 03/04/4b).
Inclusion criteria. All patients identified with an AAA
through the Chichester AAA screening program between
January 1984 and January 2007 were considered for the
study. Although the program targets men, women who
were incidentally found to have a small AAA by the local
vascular service were offered surveillance within the pro-
gram. Patients were excluded for not having more than one
ultrasound scan measurement of aneurysm diameter or if
the follow-up time was 3 months.
Patient follow-up. Patients were invited to attend
AAA surveillance clinics where they would be asked to
complete a detailed questionnaire of risk factors and cur-
rent medications before having three separate automated
blood pressure readings and a B-mode ultrasound (AP and
transverse) measurement of their AAA diameter. The inter-
val between follow-up was determined by the maximal
AAA diameter at the previous visit (4.5 cm yearly and
4.5 cm every 3 months).
Patient demographics. Cardiovascular risk factors for
each AAA patient, including hypertension, age, gender,
smoking history, diabetes, and ischemic heart disease, were
obtained from the surveillance unit database.
Record of prescriptions. Starting in 1984, all patients
identified with an AAA through screening or referred for
AAA surveillance with a small AAA were asked to list all
current medications. This was completed under supervision
at the time of the ultrasound scan. Records of these pre-
scriptions were updated at each surveillance visit through a
questionnaire completed at the time and entered into a
purpose-built database that estimated the start date of each
prescription (the date the drug was first mentioned) and the
end of each prescription (the date when the drug was first
omitted from the questionnaires). Validation of prescrip-
tions kept on the database was performed using repeat
prescriptions provided from a single general practice sur-gery for the time period (Supplement Table A, online
only). All categories of regular medication, categorized
according to the British National Formulary (BNFno. 53,
March 2007. Royal Pharmaceutical Society of Great Britain
Publishing Group, UK) with potential relevance to AAA
pathophysiology, and with a prescription frequency of1%
were included (Table I).
Statistical analysis of growth rates. AAA growth
rates were modeled using a likelihood-based, multilevel
model adapted from Brady et al.9 The analysis of growth
rates by this model can be thought of as having two distinct
steps, although the model actually combines these steps in
a single function. The first of these steps analyzes within-
subject variation. Serial measurements are collated for each
AAA patient. To adapt this for the purpose of measuring
differences in growth rate by prescription, only AAA serial
measurements that corresponded to the prescription period
were selected (the remaining portions of the growth plot
for that individual were excluded from that particular anal-
ysis). Linear and quadratic time effects and mean arterial
pressure (MAP) measures during the same period were
used as predictors of these serial measurements, and an
adjusted linear growth rate was obtained.
The second level of analysis (between-subjects) com-
pared growth rates between these two groups. Patients
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COPD medication 3.1 Bronchodilators
BNF, British National Formulary; COPD, chronic obstructive pulmonary
disease.taking the drug under investigation were placed in the
erpre
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sponded to the period they were exposed to the drug). All
patients not taking the drug under investigation were
placed in a comparison group. A further adjustment was
made, so that each group reflected a common average
baseline diameter, or start point, and adjustment was made
for covariates (age at baseline, MAP, gender, and smoking
history) between the groups.
The models were fitted using Markov Chain Monte
Carlomethods as implemented inMLwin software.10 Non-
informative priors were used. Intercept, slope, and curva-
ture terms were assumed to follow a multivariate normal
distribution. Slope, curvature, and MAP effect were al-
lowed to vary for each individual. Confounders were in-
cluded as fixed-effect covariates and the cross-level interac-
tions of drug category with time were tested to compare
growth rates for these groups. Observations censored due
to surgery were considered missing at random .The steps of
analysis are summarized in Fig 1.
Multivariate analysis. A third level of analysis was
added. A multivariate model was fitted to determine which
categories of drug were independently associated with
changes in growth rate. Terms for age, smoking, gender,
and blood pressure were forced into the model to ensure
that associations were independent of these factors. Vari-
ables for drug categories were then entered into the model
one at a time, adding the variable most strongly associated
with growth rate at each step, until there were no more
variables that added significantly to the model. The P value
for entry was .05. For these models, measurements during
the entire follow-up period were used.
RESULTS
Of 1649 patients considered for the study, 380 patients
Fig 1. Summary of analytical process used in intwere excluded (244 patients with 2 AAA measurements,53 patients with AAA diameter of3 cm, 83 patients with
3 months follow-up), leaving 1269 AAA patients. Of
these, 335 underwent elective AAA repair, and the AAA in
88 patients ruptured, of whom 71 were considered unfit or
had declined repair (Fig 2).
The average adjusted growth rate for AAAs under
surveillance was 1.97 mm/y, with the median AAA starting
at 35 mm and growing to 44 mm during a 3.4-year period
(Table II). Female gender was associated with a 42% lower
AAA growth rate of0.84 mm/y (95% confidence interval
[CI],1.37 to0.31 mm/y; P .002). Current smoking
was associated with 24% higher AAA growth rate of 0.56
mm/y (95% CI, 0.29-0.83 mm/y) compared with non-
smokers (including ex-smokers; P  .001). No significant
ting the data. AAA, Abdominal aortic aneurysm.
Fig 2. Schematic representation shows patients included in the
study and outcomes.differences in AAA growth were detected between ages or
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lance visits combined.
In a multivariate model adjusting for curvature, base-
line diameter, MAP, age at baseline, gender, and smoking
history, patients taking hypoglycemic medications had a
56% slower AAA growth rate (P .01), those treated with
angiotensin-receptor blockers (ARBs) had a 47% slower
AAA growth rate (P .04), and those treated with potassium-
sparing diuretics had a 71% slower AAA growth rate (P 
.05; Table III). When all classes of therapeutic agent were
added to the multivariate model, only diabetic medications
were independently associated with AAA growth rate (P 
.003), accounting for 2.7% of the variability. Smoking and
female gender were the risk factors that showed an inde-
pendent association with AAA growth rate.
DISCUSSION
This study used complex growth modeling and multi-
variate analysis to provide meaningful commentary on 25
years of prospectively collected data on 1269 AAA patients.
To our knowledge, this is the longest reported continuous
collection of AAA data and provides an opportunity for
comparison of cardiovascular risk factors and 5000
prescriptions with AAA growth rates. Current prescrib-
ing guidelines would make it difficult to find a compara-
ble group of AAA patients not taking, for example,
statins, but because of the historical nature of this co-
hort, more than two-thirds of patients were not exposed
to statin therapy during the course of the study. Al-
though including 25 years of data does introduce the risk
of temporal bias, we believe the nature of AAA patho-
physiology is unlikely to have changed in this time frame,
and risk factors of age, blood pressure, gender, and
smoking history, which may have altered over time, were
adjusted for in the analysis.
Advantages of this analysis over previously reported
retrospective association studies include adjustment of
AAA growth rates based on multilevel modeling, adjust-
ment of MAP over time, and inclusion of AAA measure-
ments for analysis related only to periods of exposure to the
medication in question (reducing comparison of individual
variation between patients). Although compliance is an
Table II. Patient characteristics
Variable Result
Final AAA diameter, mean
(IQR) mm 44 (35-56)
Start diameter, mean (IQR) mm 35 (31-42)
Follow-up time, mean (IQR) y 3.4 (2.0-6.5)
Age, mean (IQR) y 67 (65-71)
Female, No. (%) 75 (5.9)
Current smokers, No. (%) 403 (32.8)
Growth rate, mean (SE) mm/
y [95% CI] 1.97 (0.11) [1.60 to 5.54]
AAA, Abdominal aortic aneurysm; CI, confidence interval; IQR, interquar-
tile range; SE, standard error.issue in any therapeutic study because of the nature of thewithin-group comparison, any noncompliance in one
group is likely to be balanced in another, resulting in a
reduction of power to detect differences but not in false-
positive results.
Smoking was associated with an increased AAA growth
rate, but this was not true for serial MAP measurements or
a history of hypertension, as has previously been reported.9
Unexpectedly, female gender was associated with slowed
adjusted AAAgrowth, although numbers of womenwere low
(n  75). This finding contradicts those of two other
studies11,12 and has been discussed by this group in more
detail elsewhere.4 In summary, AAA size, distribution, age,
and gender fit the expectations of a screening program
targeting men at 65 years.
Exposure to hypoglycemic medication was the single
association with therapeutic agents to maintain significance
through multivariate analysis (P .003). This is supported
by several studies that demonstrated a protective role for
diabetes in AAA expansion.9,13,14 No single subclass of
diabetic therapeutic agent had a greater effect than any
other (P .05, Supplement Table B, online only), making
it likely that diabetes has the protective role rather than the
actions of its therapeutic agents. Almost all patients identi-
fied as diabetic through the questionnaires were receiving
medication (17 were diet controlled); thus, it was not
possible to confirm the effects of diabetes on AAA growth
outside of those medicated patients.
ARBs and potassium-sparing diuretics demonstrated
significant associations with slowed AAA growth rate sep-
arate of their effects onMAP. The actions of ARBs through
the angiotensin-1 (AT1) receptor of the RAS are well
reported. Potassium-sparing diuretics act by blocking aldo-
sterone receptors, aldosterone being released through acti-
vation of the AT1 receptor. Several groups have reported
on the effects of blocking the AT1 receptor and the effects
of aldosterone in murine models of AAA disease,15,16 but
to our knowledge this is the first time that agents affecting
these components of the RAS have been associated with
altered AAA growth in a clinical study.
ACE inhibitors, in contrast with a previous large cohort
study looking at rupture rates,8 was not associated with
slowed AAA growth rate. However, inclusion of ACE as a
drug affecting the RAS (along with ARBs and potassium-
sparing diuretics) strengthened the power of the associa-
tion with slowed AAA growth rate (Supplement Table B,
online only).
Demonstrating independent effects in these therapeu-
tic agents through multivariate analysis was not possible
due to the polypharmaceutical approach taken to address
cardiac risk factors in many of these patients. However, in
the context of existing evidence that the RAS plays a strong
role in the pathophysiology of AAA disease,17 this should
be seen as evidence that drugs affecting the RAS are likely to
slow AAA growth.
The overall trend for AAA exposed to categories of
therapeutic agents is for slowed AAA growth, with the
notable exception of drugs to suppress rheumatic disease,
which includes methotrexate, azathioprine, and penicilla-
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(95% CI) P value
Statins
No 840 6919 1.54 (0.14) 0
Yes 357 3531 1.47 (0.20) 0.07 (0.45 to 0.32) .73
NSAIDS
No 1102 9181 1.53 (0.14) 0
Yes 120 1269 1.03 (0.31) 0.51 (1.13 to 0.08) .11
Rheumatic disease suppressants
No 1231 10339 1.64 (0.23) 0
Yes 13 111 3.93 (1.28) 2.29 (0.20 to 4.78) .07
Corticosteroids
No 1165 9775 1.49 (0.13) 0
Yes 74 675 1.73 (0.32) 0.24 (0.38 to 0.87) .45
Drugs to treat gout
No 1175 9844 1.57 (0.13) 0
Yes 63 606 1.14 (0.38) 0.43 (1.16 to 0.30) .25
-Blockers
No 1030 9729 1.81 (0.23) 0
Yes 69 721 2.27 (0.42) 0.45 (0.28 to 1.18) .23
ACE inhibitors
No 834 7777 2.04 (0.24) 0
Yes 265 2673 1.76 (0.27) 0.28 (0.67 to 0.12) .17
ARBs
No 1026 9869 1.94 (0.23) 0
Yes 73 581 1.03 (0.48) 0.91 (1.78 to 0.03) .04
-blockers
No 773 7138 1.96 (0.24) 0
Yes 326 3312 1.77 (0.27) 0.19 (0.55 to 0.16) .29
Calcium channel blockers
No 808 7441 1.97 (0.24) 0
Yes 291 3009 1.68 (0.27) 0.29 (0.66 to 0.08) .12
Thiazides, related diuretics
No 912 8559 1.95 (0.24) 0
Yes 187 1891 2.03 (0.30) 0.09 (0.37 to 0.54) .71
Antiplatelet drugs
No 757 6183 1.54 (0.15) 0
Yes 443 4267 1.35 (0.83) 0.19 (0.53 to 0.12) .26
Oral anticoagulants
No 1168 9678 1.52 (0.14) 0
Yes 68 772 1.27 (0.33) 0.26 (0.92 to 0.39) .43
Positive inotropic drugs (cardiac glycosides)
No 1182 9838 1.56 (0.14) 0
Yes 54 612 1.34 (0.35) 0.21 (0.91 to 0.47) .55
Antiarrhythmic drugs
No 1210 10150 1.52 (0.13) 0
Yes 30 300 1.09 (0.73) 0.46 (1.87 to 0.98) .53
Nitrates
No 1087 8943 1.49 (0.14) 0
Yes 143 1507 1.27 (0.43) 0.21 (0.66 to 0.24) .36
Potassium-channel activators
No 1231 10306 1.47 (0.13) 0
Yes 12 144 1.85 (1.13) 0.39 (1.86 to 2.63) .73
Diabetic medication
No 1163 9928 1.70 (0.23) 0
Yes 69 522 0.74 (0.40) 0.95 (1.66 to 0.25) .01
Loop diuretics
No 1096 9066 1.53 (0.13) 0
Yes 130 1384 1.17 (0.26) 0.36 (0.87 to 0.25) .16
Potassium-sparing diuretics
No 1208 10111 1.58 (0.13) 0
Yes 31 339 0.49 (0.55) 1.09 (2.17 to 0.06) .05
Potassium-sparing diuretics  other diuretics
No 1175 9759 1.52 (0.13) 0
Yes 62 691 1.19 (0.37) 0.33 (1.03 to 0.37) .36
dard
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increase in growth rate. This suggests that immunosuppres-
sive drugs may destabilize the AAA wall, permitting further
AAA expansion. A similar but less marked trend is seen with
corticosteroids. In contrast to recent reports, no association
was found with statins and altered growth rate.18,19 Ideally
the positive associations identified by this study would be
confirmed by those discontinuing therapies (a retrospective
cross-over study); however, the numbers of patients taken
off medication once started were too small for meaningful
analysis.
A criticism of observational studies has been the inabil-
ity to exclude covariates as a causal factor when reporting an
association. This study attempted to address this point by
using a multivariate model to analyze all possible covariates
(risk factors and categories of therapeutic agents). This
exposed the study to errors of multiple testing; however,
correctionmethods such as the Bonferroni method are very
conservative and increase the likelihood of type II errors,
meaning that important differences may be missed. Errors
of interpretation are less when no adjustment is made.20,21
For this reason all associations with a value of P .05 have
been reported as significant in this study but with a warning
that some findings may be due to statistical chance rather
than a true association. Multivariate analysis has provided a
tool to assess the independence of associations; however,
associations that cannot prove independence may still be
true and should be considered within the context of all
available evidence. The alternative to observational studies
is controlled trials, but these are likely to be unpalatable to
patients and ethics boards because many of the drugs in
question have proven benefits for risk modification in these
patients.
Embracing the approach put forward in this study of
including all covariates requires very large numbers. Even
this cohort of1200 patients followed-up for 25 years was
unable to demonstrate independence for several of the
observed associations. With the advent of national AAA
screening programs, an opportunity is available to compile
databases that are large enough to demonstrate indepen-











Drugs acting on the RASa
No 817 73
Yes 392 30
AAA, Abdominal aortic aneurysm; RAS, renin-angiotensin system; SE, stan
aAngiotensin-converting enzyme inhibitors, angiotensin-receptor blockers,gression (expansion and rupture).CONCLUSIONS
In studying AAA growth modulation, the importance
of historical observational data is paramount considering
the difficult ethical implications of devising cohort studies
using established treatments for coexisting pathologies.
Although analysis of such data is complex and interpreta-
tion of results difficult, conclusions can still be drawn. This
large study found diabetes and smoking were indepen-
dently associated with altered AAA growth rate. Drugs
influencing the RAS, in particular ARBs and aldosterone-
receptor blockers, may reduce the rate of AAA growth, but
these associations need confirmation from similar observa-
tional studies or prospective studies.
We acknowledge the pioneering work of Alan Scott in
the field of AAA screening in general and in establishing the
Chichester AAA screening program in particular.
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with a sensitivity of 72% (75 of 104).
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from a single general practitioner assessing questionnaire





Present (77) 75 2
Absent 29 Unknown
aIf the general practitioner records are taken as the gold standard, then the
positive-predictive value of the test (questionnaires) was 97% (75 of 77),
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Drug No. Mean growth rate per year (SE) Estimated difference in AAA growth rate (95% CI) Pa
Biguanides
No 1190 1.55 (0.13) 0
Yes 47 0.75 (0.40) 0.80 (1.60 to 0.008) .05
Insulins
No 1236 1.51 (0.13) 0
Yes 8 0.18 (1.59) 1.33 (4.44 to 1.78) .40
Sulfonylureas
No 1193 1.59 (0.13) 0
Yes 42 0.70 (0.41) 0.89 (1.71 to 0.07) .03
Other anti-diabetic
No 1231 1.52 (0.13) 0
Yes 13 0.67 (1.15) 0.85 (3.11 to 1.41) .46aNo significant difference in abdominal aortic aneurysm growth rates between subgroups of diabetic medication (P  .05).
